Search results
ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations
FierceBiotech· 3 days agoAnalysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days agoCHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 3 days agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...
Christopher Sarchi Sells 2,218 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock
ETF DAILY NEWS· 5 days agoReplimune Group, Inc. (NASDAQ:REPL – Get Free Report) insider Christopher Sarchi sold 2,218 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were ...
Brokers Issue Forecasts for Replimune Group, Inc.’s Q1 2025 Earnings (NASDAQ:REPL)
ETF DAILY NEWS· 6 days agoReplimune Group, Inc. (NASDAQ:REPL – Free Report) – Analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Replimune Group in a note issued to investors on ...
Rutgers Cancer Institute and RWJBarnabas Health Set to Unveil Extensive, New Cancer Research...
Benzinga· 3 days ago49 scheduled presentations will explore several types of cancer, as well as the next frontier of health equity NEW BRUNSWICK, N.J., May 23, 2024 /PRNewswire/ -- Clinicians and scientists from Rutgers Cancer Institute and
Regeneron (REGN) Announces Positive Data on Oncology Candidate
Zacks· 3 days agoFree Report) announced positive new results from an ongoing phase I/II study on pipeline candidate REGN7075. The phase I/II first-in-human, open-label study is evaluating REGN7075, in combination ...